Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2022 | 1417 | 1.250 |
Why?
|
| Nuclear Receptor Coactivator 3 | 5 | 2021 | 257 | 1.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 1988 | 0.950 |
Why?
|
| Tumor Microenvironment | 4 | 2026 | 704 | 0.870 |
Why?
|
| Tumor Hypoxia | 1 | 2024 | 7 | 0.850 |
Why?
|
| Photoacoustic Techniques | 1 | 2024 | 6 | 0.850 |
Why?
|
| Glutamine | 2 | 2022 | 202 | 0.790 |
Why?
|
| Bone Neoplasms | 3 | 2024 | 444 | 0.760 |
Why?
|
| Cell Plasticity | 1 | 2022 | 37 | 0.740 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 2646 | 0.680 |
Why?
|
| Aconitate Hydratase | 1 | 2020 | 12 | 0.670 |
Why?
|
| Sirtuin 3 | 1 | 2020 | 31 | 0.660 |
Why?
|
| Transcriptional Activation | 3 | 2018 | 414 | 0.620 |
Why?
|
| Phosphofructokinase-2 | 1 | 2018 | 23 | 0.560 |
Why?
|
| Nuclear Receptor Coactivator 2 | 3 | 2015 | 150 | 0.540 |
Why?
|
| Glucose | 2 | 2018 | 848 | 0.490 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1617 | 0.470 |
Why?
|
| Cell Line, Tumor | 13 | 2026 | 3672 | 0.450 |
Why?
|
| Mitochondria | 1 | 2020 | 759 | 0.450 |
Why?
|
| Transcription, Genetic | 4 | 2015 | 1397 | 0.410 |
Why?
|
| Neoplasms | 2 | 2022 | 2969 | 0.400 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2013 | 60 | 0.400 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2022 | 356 | 0.370 |
Why?
|
| Energy Metabolism | 2 | 2015 | 783 | 0.360 |
Why?
|
| Reproduction | 1 | 2013 | 215 | 0.360 |
Why?
|
| Annexin A2 | 3 | 2019 | 5 | 0.350 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2026 | 177 | 0.340 |
Why?
|
| Mice | 14 | 2026 | 18473 | 0.330 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 711 | 0.320 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 2355 | 0.310 |
Why?
|
| Glycolysis | 2 | 2022 | 171 | 0.310 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 1541 | 0.300 |
Why?
|
| Animals | 17 | 2026 | 34341 | 0.300 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 287 | 0.290 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2023 | 100 | 0.290 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 418 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 1001 | 0.290 |
Why?
|
| Receptors, Estrogen | 2 | 2024 | 722 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 825 | 0.280 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 588 | 0.270 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2464 | 0.270 |
Why?
|
| Phosphorylation | 5 | 2018 | 1570 | 0.260 |
Why?
|
| Pancreatic Neoplasms | 2 | 2026 | 731 | 0.250 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 676 | 0.250 |
Why?
|
| Alprazolam | 1 | 2026 | 7 | 0.250 |
Why?
|
| Mice, Nude | 2 | 2020 | 714 | 0.250 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2026 | 23 | 0.240 |
Why?
|
| Cell Movement | 4 | 2018 | 879 | 0.220 |
Why?
|
| IMP Dehydrogenase | 1 | 2025 | 27 | 0.220 |
Why?
|
| Transcription Factors | 1 | 2014 | 2436 | 0.220 |
Why?
|
| Doxorubicin | 1 | 2025 | 300 | 0.200 |
Why?
|
| TNF Receptor-Associated Factor 4 | 2 | 2023 | 14 | 0.190 |
Why?
|
| Humans | 23 | 2026 | 131504 | 0.190 |
Why?
|
| Citric Acid Cycle | 1 | 2022 | 43 | 0.190 |
Why?
|
| Circadian Rhythm | 2 | 2015 | 315 | 0.180 |
Why?
|
| Mice, SCID | 3 | 2018 | 579 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 647 | 0.160 |
Why?
|
| Cytokines | 1 | 2026 | 1347 | 0.160 |
Why?
|
| Genes, myc | 1 | 2019 | 95 | 0.160 |
Why?
|
| Castration | 1 | 2019 | 31 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2024 | 972 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 989 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 234 | 0.150 |
Why?
|
| Metabolomics | 1 | 2022 | 493 | 0.140 |
Why?
|
| Phosphoserine | 1 | 2018 | 38 | 0.140 |
Why?
|
| Transketolase | 1 | 2018 | 17 | 0.140 |
Why?
|
| Receptor, trkA | 1 | 2018 | 18 | 0.140 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 44 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 361 | 0.140 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 35 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 115 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 256 | 0.130 |
Why?
|
| Prognosis | 4 | 2025 | 4951 | 0.130 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 329 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2019 | 2567 | 0.130 |
Why?
|
| Hexosamines | 1 | 2016 | 18 | 0.120 |
Why?
|
| RNA Interference | 1 | 2018 | 496 | 0.120 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Male | 12 | 2023 | 65158 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2015 | 23 | 0.120 |
Why?
|
| E2F1 Transcription Factor | 1 | 2016 | 49 | 0.120 |
Why?
|
| Protein Binding | 3 | 2015 | 1710 | 0.120 |
Why?
|
| Female | 9 | 2025 | 71087 | 0.110 |
Why?
|
| Lipogenesis | 1 | 2015 | 62 | 0.110 |
Why?
|
| Gene Expression | 2 | 2015 | 1500 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 442 | 0.100 |
Why?
|
| Apoptosis | 1 | 2020 | 1861 | 0.100 |
Why?
|
| Mouth Neoplasms | 1 | 2015 | 98 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2015 | 694 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 194 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2015 | 464 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1276 | 0.100 |
Why?
|
| DNA | 2 | 2016 | 1443 | 0.090 |
Why?
|
| Cell Survival | 1 | 2015 | 853 | 0.090 |
Why?
|
| Chromatin | 1 | 2015 | 491 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2013 | 810 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 713 | 0.090 |
Why?
|
| Metabolome | 1 | 2014 | 329 | 0.090 |
Why?
|
| Liver | 2 | 2015 | 1795 | 0.080 |
Why?
|
| STAT6 Transcription Factor | 1 | 2010 | 32 | 0.080 |
Why?
|
| Ubiquitination | 2 | 2023 | 173 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2019 | 4674 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2014 | 894 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2019 | 832 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 382 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2019 | 448 | 0.060 |
Why?
|
| ARNTL Transcription Factors | 2 | 2015 | 46 | 0.060 |
Why?
|
| Disease Progression | 3 | 2019 | 2205 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 483 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 114 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 665 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2024 | 305 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2022 | 158 | 0.040 |
Why?
|
| Androgens | 1 | 2023 | 272 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2021 | 3861 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2019 | 439 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 301 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 195 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 955 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 909 | 0.030 |
Why?
|
| Glucokinase | 1 | 2015 | 13 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2015 | 17 | 0.030 |
Why?
|
| DNA Repair | 1 | 2019 | 562 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 83 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2015 | 83 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1522 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2985 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1322 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2015 | 195 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2015 | 135 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 190 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 344 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 362 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 198 | 0.030 |
Why?
|
| CLOCK Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 275 | 0.030 |
Why?
|
| DNA Replication | 1 | 2016 | 359 | 0.030 |
Why?
|
| Cadherins | 1 | 2014 | 178 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 598 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 400 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 1202 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 262 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1599 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1078 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2603 | 0.020 |
Why?
|
| Models, Biological | 1 | 2015 | 1390 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2010 | 61 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2015 | 1024 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 145 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5120 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 233 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 28839 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 758 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 312 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 659 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1162 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1809 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 17648 | 0.010 |
Why?
|